ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
FREDERICK, Md., April 8 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their novel small molecule piperazine compound for the treatment of solid tumors at the Targeted Cancer Therapeutics meeting held in Whistler, British Columbia. The presentation highlighted advances in the development of ImQuest's lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent antiproliferative activity against a variety of tumor cell types (prostate, lung, ovary, colon, CNS, melanoma, and hematopoietic lineages) by disruption of cell cycle progression and induction of apoptosis with a secondary anti-angiogenic activity as a consequence of the cytoskeletal disruption. The unique activity, novel structure, potent in vivo efficacy in murine xenograft models, as well as a favorable toxicity profile, potential for oral bioavailability and straight-forward cGMP manufacturing suggest that IQP-0304 might be an important addition to the currently available therapeutic regimens used to treat solid tissue malignancies. Dr. Nick Kaludov, Ph.D., Director of Scientific Operations, presented the new findings which also included toxicology and toxicokinetic evaluations.
"These results highlight the significant potential of the piperazines as highly potent and broadly active chemotherapeutic agents and provide additional rationale for their expedited development," said Dr. Robert W. Buckheit Executive Vice President and Chief Scientific Officer, and presentation co-author.
ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.
For further information regarding this press release please contact: Robert W. Buckheit, Jr., Ph.D. Executive Vice President and Chief Scientific Officer ImQuest Life Sciences, Inc. 301-696-0274 email@example.com
Source: ImQuest Life Sciences, Inc.
CONTACT: Robert W. Buckheit, Jr., Ph.D., Executive Vice President and
Chief Scientific Officer of ImQuest Life Sciences, Inc., +1-301-696-0274,
Web Site: http://www.imquest.com/
Posted: April 2009